Roche publishes new sclerosis data to keep Novartis at bay

With the recently approved sclerosis treatment, Kesimpta, first developed by Genmab, Novatis is in full swing competing with Roche's dominant medicine on the market. Now Roche attempts retaliation.

Photo: Alexandra Wey/AP/Ritzau Scanpix

New data on the use of Roche’s MS treatment Ocrevus in the early stages of the illness will give it a new boost, writes sector media Fiercepharma.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs